Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Shahid Beheshti Medical University.
Recruitment status was  Recruiting
Information provided by:
Shahid Beheshti Medical University Identifier:
First received: October 13, 2009
Last updated: October 21, 2009
Last verified: October 2009
In this study 126 eyes in 63 patients with moderate bilateral myopia and astigmatism between -3 and -5 (SE difference between two eyes should not be more than 0.75 and the residual corneal thickness>350 μ ) were entered in the study. One eye went randomly under PRK with mitomycin C 0.02% in 15 min and then the other eye went under the operation without MMC. UCVA,BCVA, refractory error after the operation and the number of endothelial cells before and after the surgery would be compared in 6 months.

Condition Intervention Phase
Drug: Mitomycin C 0.02%
Drug: Placebo
Phase 1

Study Type: Interventional
Official Title: Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti Medical University:

Study Start Date: September 2009
Arms Assigned Interventions
Active Comparator: Mitomycin c 0.02% Drug: Mitomycin C 0.02%
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   19 Years to 60 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • 19 < age < 60
  • Refractory error stabled for at least one year
  • No corneal pathology
  • -3 < bilateral myopia and astigmatism < -5 with no difference more than 0.75 between 2 eyes

Exclusion criteria:

  • Keratoconus
  • Ectatic corneal disease
  • Glaucoma
  • Corneal dystrophy
  • Lens changes affecting the visual acuity
  • Anterior or posterior uveitis
  • Corneal scar
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00999973

Contact: Mohammad Ali Javadi, MD +982122585952

Iran, Islamic Republic of
Ophthalmic Research Center Recruiting
Tehran, Iran, Islamic Republic of, 166666
Contact: Mohammad Ali Javadi, MD         
Sponsors and Collaborators
Shahid Beheshti Medical University
  More Information

No publications provided Identifier: NCT00999973     History of Changes
Other Study ID Numbers: 8804 
Study First Received: October 13, 2009
Last Updated: October 21, 2009
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Eye Diseases
Refractive Errors
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses processed this record on February 11, 2016